Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune hemolytic anemia and IgG4-related…Read More
You might also be interested in reading AtriCure targets $517M-$527M revenue in 2025 with new product launches and international growth.